A 55-year-old postmenopausal woman from Delhi undergoes mammography for screening and is found to have a 1.2 cm mass in the upper outer quadrant of the right breast (BI-RADS 4). Core needle biopsy confirms invasive lobular carcinoma (ILC), grade I, hormone receptor positive. Clinical examination reveals no palpable axillary lymph nodes. Staging imaging (CT chest/abdomen, bone scan) is normal. The patient is counseled about treatment options. What is the most appropriate surgical management?

Explanation

## Clinical Scenario Analysis This patient has: - **Small tumor** (1.2 cm) — T1 disease - **Invasive lobular carcinoma (ILC)**, grade I — favorable histology - **Hormone receptor positive** — endocrine-responsive - **Clinically node-negative** (cN0) — no palpable axillary nodes - **Normal staging investigations** — M0 - **Age 55** — postmenopausal, suitable for BCT ## Breast-Conserving Therapy (BCT) Eligibility **Key Point:** Breast-conserving therapy (wide local excision + radiotherapy) is the preferred approach for early-stage breast cancer when: 1. Tumor ≤ 5 cm (ideally < 3 cm) 2. Clinically node-negative (cN0) 3. No multicentric disease 4. Negative margins achievable 5. Patient desires breast conservation 6. Radiotherapy accessible and acceptable This patient meets ALL criteria for BCT. ## Axillary Management in cN0 Disease ```mermaid flowchart TD A[Early breast cancer, cN0]:::outcome --> B[BCT candidate?]:::decision B -->|Yes| C[Wide local excision]:::action C --> D[Sentinel Lymph Node Biopsy]:::action D --> E{SLNB positive?}:::decision E -->|No| F[Radiotherapy to breast]:::action E -->|Yes| G[Consider ALND or ACOSOG Z0011 criteria]:::decision F --> H[Adjuvant systemic therapy per receptor status]:::action B -->|No| I[Mastectomy ± ALND]:::action ``` **High-Yield:** In clinically node-negative patients, **sentinel lymph node biopsy (SLNB)** is the standard of care. It provides accurate staging with minimal morbidity compared to ALND. ALND is reserved for: - Clinically positive nodes (cN1–cN3) - Positive SLNB (with exceptions per ACOSOG Z0011 trial) - Therapeutic intent in advanced disease ## Why Wide Local Excision + SLNB + Radiotherapy? 1. **Tumor size and stage** → T1N0M0 is ideal for BCT 2. **Equivalent survival** → BCT + radiotherapy has equivalent 10-year overall survival to mastectomy in early-stage disease [cite:EBCTCG meta-analysis] 3. **Reduced morbidity** → SLNB avoids ALND-related lymphedema (10–20% risk) and nerve injury 4. **Radiotherapy is essential** → Reduces local recurrence from ~20% to ~5% in BCT 5. **Hormone receptor positive** → Adjuvant endocrine therapy (aromatase inhibitor or tamoxifen) will further reduce recurrence risk **Clinical Pearl:** Invasive lobular carcinoma (ILC) has a higher propensity for bilaterality and multicentric disease compared to IDC. However, with a single 1.2 cm lesion and normal imaging, BCT is still appropriate. Close follow-up and contralateral breast surveillance are essential. ## Staging Summary - **TNM:** T1N0M0 (Stage IA) - **Surgical approach:** Wide local excision + SLNB + radiotherapy - **Systemic therapy:** Adjuvant endocrine therapy (aromatase inhibitor ± tamoxifen based on menopausal status and risk factors)